Systemic Scleroderma Clinical Trial
Official title:
Effects of a Personalized Standardized Rehabilitation Program on the Quality of Life of Patients With Systemic Sclerosis Patients : a Randomized Controlled Trial
Systemic sclerosis (SSc) is a connective-tissue disease characterized by excessive collagen deposition, vascular hyper-reactivity and obliterative microvascular phenomena leading to disability, handicap, and worsening of quality of life. Pharmacological treatments are mainly used for vascular involvement. To date, no pharmacological treatment have been shown to be effective for the fibrosis leading to skin, tendon, and joint disability. Our hypothesis is that rehabilitation could be an interesting non pharmacological treatment in order to decrease the handicap of SSc patients. Our objective is to evaluate the effect of a personalized standardized rehabilitation program on the quality of life of SSc patients in a multicentric randomized controlled trial. This trial will compare a personalized standardized rehabilitation program to the usual non pharmacological treatment. The primary outcome measure will be the HAQ DI (Health Assessment Questionnaire Disability Index). A Zelen design will be used for this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03629002 -
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
|
||
| Terminated |
NCT00377455 -
Placebo Controlled Trial of Bosentan in Scleroderma Patients
|
Phase 2 | |
| Completed |
NCT00278525 -
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
|
Phase 2 | |
| Completed |
NCT03575156 -
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
|
N/A | |
| Active, not recruiting |
NCT01413100 -
Scleroderma Treatment With Autologous Transplant (STAT) Study
|
Phase 2 | |
| Completed |
NCT00622895 -
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03816189 -
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
|
||
| Completed |
NCT01295736 -
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
|
Phase 3 | |
| Completed |
NCT02213705 -
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03508375 -
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
|
N/A | |
| Active, not recruiting |
NCT01309997 -
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Completed |
NCT00697736 -
Cardiac Repercussion of Systemic Sclerodermias
|
N/A | |
| Completed |
NCT02349009 -
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT00318175 -
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT03262922 -
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
|
||
| Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
| Recruiting |
NCT04380831 -
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
|
Early Phase 1 | |
| Terminated |
NCT00628797 -
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05672992 -
Longitudinal Spatial Frequency Domain Imaging Study
|
N/A | |
| Recruiting |
NCT05726630 -
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
|
Phase 3 |